Criteria to qualify for study: | Drug used in study: |
---|---|
|
LYM 188 A Phase 1b/ll study of safety, tolerability and efficacy of APG-2575 alone or in combination with other therapeutic agents in patients with Waldenstrom Macroglobulinemia. https://clinicaltrials.gov/ct2/results?cond=&term=NCT04260217 |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
LYM 165 A Phase 1b Trial of Mavorixafor, an oral CXCR4 Antagonist, in combination with Ibrutinib in patients with Waldenstrom’s Macroglobulinemia (WM) whose tumors express mutations of MYD88 and CXCR4 |